Don Alexander Gabriel

US Patent:

6498273, Dec 24, 2002

Filed:

May 25, 2001

Appl. No.:

09/866243

Inventors:

Don A. Gabriel - Carrboro NC
Laura J. Melton - Durham NC

Assignee:

The University of North Carolina - Chapel Hill NC

International Classification:

C07C23305

US Classification:

564153, 424 9452, 514330, 514423, 514424, 514616, 546226, 548540

Abstract:

The present invention provides basic ionic contrast agents that have anticoagulant activity. The contrast media incorporate a lysine or arginine group or derivative, and have a free amino or guanidino group. Methods of using the contrast media are also disclosed.

US Patent:

6610850, Aug 26, 2003

Filed:

Sep 27, 2002

Appl. No.:

10/259067

Inventors:

Don A. Gabriel - Carrboro NC
Laura J. Melton - Durham NC

Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

C07D21108

US Classification:

546189, 546226, 514316, 514330, 424 944

Abstract:

The present invention provides basic ionic contrast agents that have anticoagulant activity. The contrast media incorporate a lysine or arginine group or derivative, and have a free amino or guanidino group. Methods of using the contrast media are also disclosed.

US Patent:

6943269, Sep 13, 2005

Filed:

Jun 20, 2003

Appl. No.:

10/601026

Inventors:

Don A. Gabriel - Carrboro NC, US
Laura J. Melton - Durham NC, US

Assignee:

University of North Carolina - Chapel Hill - Chapel Hill NC

International Classification:

C07C233/05
A61K031/16

US Classification:

564153, 514330, 514423, 514424, 514616, 546226, 548540, 424 9452

Abstract:

The present invention provides basic ionic contrast agents that have anticoagulant activity. The contrast media incorporate a lysine or arginine group or derivative, and have a free amino or guanidino group. Methods of using the contrast media are also disclosed.

US Patent:

7771660, Aug 10, 2010

Filed:

May 3, 2005

Appl. No.:

11/121322

Inventors:

Don A. Gabriel - Carrboro NC, US

Assignee:

University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

G01N 15/06
G01N 33/00
G01N 33/48
G01N 33/483
G01N 33/49
G01N 33/50
G01N 33/53
G01N 33/555
G01N 33/556
G01N 33/569

US Classification:

422 8205, 422 50, 422 63, 422 681, 422 8201, 422100, 422101, 422102, 435 4, 435 5, 435 6, 435 71, 435 72, 435 721, 435 722, 435 723, 435 724, 435 725, 435 731, 435 732, 435 29, 435 30, 435 34, 435 38, 435 39, 435 40, 4352885, 4352887

Abstract:

Methods for identifying a biological particle in a sample medium include generating an Electrophoretic Quasi-elastic Light Scattering (EQELS) spectrum for the biological particle in the sample medium. The EQELS spectrum is compared to a reference database comprising a plurality of spectra, and each of the plurality of spectra correspond to an EQELS spectrum for one of a plurality of known biological particles. The biological particle in the sample medium is identified from the comparison.

US Patent:

8455207, Jun 4, 2013

Filed:

Jul 30, 2009

Appl. No.:

12/512321

Inventors:

Don A. Gabriel - Carrboro NC, US

Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

G01N 33/53
A61K 33/00

US Classification:

435 72

Abstract:

Methods for identifying a biological particle in a sample medium include generating an Electrophoretic Quasi-elastic Light Scattering (EQELS) spectrum for the biological particle in the sample medium. The EQELS spectrum is compared to a reference database comprising a plurality of spectra, and each of the plurality of spectra correspond to an EQELS spectrum for one of a plurality of known biological particles. The biological particle in the sample medium is identified from the comparison.

US Patent:

8551405, Oct 8, 2013

Filed:

Jul 30, 2009

Appl. No.:

12/512306

Inventors:

Don A. Gabriel - Carrboro NC, US

Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

C12Q 1/04

US Classification:

422 8205

Abstract:

Methods for identifying a biological particle in a sample medium include generating an Electrophoretic Quasi-elastic Light Scattering (EQELS) spectrum for the biological particle in the sample medium. The EQELS spectrum is compared to a reference database comprising a plurality of spectra, and each of the plurality of spectra correspond to an EQELS spectrum for one of a plurality of known biological particles. The biological particle in the sample medium is identified from the comparison.

US Patent:

8551406, Oct 8, 2013

Filed:

Jul 30, 2009

Appl. No.:

12/512335

Inventors:

Don A. Gabriel - Carrboro NC, US

Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

C12Q 1/04

US Classification:

422 8205

Abstract:

Methods for identifying a biological particle in a sample medium include generating an Electrophoretic Quasi-elastic Light Scattering (EQELS) spectrum for the biological particle in the sample medium. The EQELS spectrum is compared to a reference database comprising a plurality of spectra, and each of the plurality of spectra correspond to an EQELS spectrum for one of a plurality of known biological particles. The biological particle in the sample medium is identified from the comparison.

US Patent:

20100035235, Feb 11, 2010

Filed:

Jul 14, 2009

Appl. No.:

12/502941

Inventors:

Don Gabriel - Carrboro NC, US

Assignee:

INVITROX, INC. - Durham NC

International Classification:

C12Q 1/70
G01N 33/53
C12Q 1/02
G01N 33/48

US Classification:

435 5, 435 71, 435 29, 436 63

Abstract:

Methods for using focused light scattering techniques for the optical sensing of biological particles suspended in a liquid medium are disclosed. The optical sensing enables one to characterize particles size and/or distribution in a given sample. This, in turn, allows one to identify the biological particles, determine their relative particle density, detect particle shedding, and identify particle aggregation. The methods are also useful in screening and optimizing drug candidates, evaluating the efficacy and dosage levels of such drugs, and in personalized medicine applications.